Trial-Based Costs for Interventions to Improve HPV Vaccine Uptake
This economic evaluation estimates the implementation costs and cost per additional patient receiving the vaccine associated with each of the intervention strategies for increasing rates of human papillomavirus (HPV) vaccination in primary care practices.
Authors
- Wei Yi Kong (ORCID: https://orcid.org/0000-0003-2434-744X)
- Jeph Herrin (ORCID: https://orcid.org/0000-0002-3671-3622)
- Joan M. Griffin (ORCID: https://orcid.org/0000-0001-8120-3229)
- Lila J. Finney Rutten (ORCID: https://orcid.org/0000-0001-7487-9407)
- Robert M. Jacobson (ORCID: https://orcid.org/0000-0002-6355-8752)
- Anna Hung (ORCID: https://orcid.org/0000-0002-0730-431X)
- Xuan Zhu (ORCID: https://orcid.org/0000-0002-6675-2155)
- Gregory D. Jenkins (ORCID: https://orcid.org/0000-0001-6408-6227)
- Kathy L. MacLaughlin (ORCID: https://orcid.org/0000-0001-8241-7587)
Institutions
- Mayo Clinic (US)
- Duke University (US)
- WinnMed (US)
- Yale University (US)
- Durham VA Health Care System (US)
- Duke Institute for Health Innovation (US)
- Mayo Clinic in Arizona (US)
- Mayo Clinic in Florida (US)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2025-12-19
- DOI
- https://doi.org/10.1001/jamanetworkopen.2025.50657
- Primary Topic
- Cervical Cancer and HPV Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- U.S. Department of Veterans Affairs
- Eli Lilly and Company
- AstraZeneca
- Moderna
- National Institutes of Health
- Genentech
- National Cancer Institute